Mineralocorticoid receptor antagonists: 60 years of research and development

Journal of Endocrinology

Volumn 234, Issue 1, 2017, Pages T125-T140

  Kolkhof, Peter ^a   Bärfacker, Lars ^a  

^a BAYER AG   (Germany)

Author keywords

Apararenone; Canrenone; Eplerenone; Esaxerenone; Finerenone; Mineralocorticoid receptor antagonists; Potassium canrenoate; Spironolactone

Indexed keywords

7ALPHA THIOMETHYLSPIRONOLACTONE; APARARENONE; CANRENOATE POTASSIUM; CANRENONE; EPLERENONE; ESAXERENONE; FINERENONE; MESPIRENONE; MEXRENOATE POTASSIUM; MINERALOCORTICOID ANTAGONIST; POTASSIUM OXPRENOATE; POTASSIUM PRORENOATE; SPIRONOLACTONE; SPIRORENONE; UNCLASSIFIED DRUG; MINERALOCORTICOID RECEPTOR;

DRUG RESEARCH; HUMAN; MOLECULAR CLONING; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; HISTORY; METABOLISM; PHYSIOLOGY; RESEARCH;

ANIMALS; GENE EXPRESSION REGULATION; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RECEPTORS, MINERALOCORTICOID; RESEARCH;

EID: 85023173577     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-16-0600     Document Type: Review

References (115)

1. Aldactone NDA. 2008. Aldactone, spironolactone tablets USP, NDA 12-151/S-062, Pfizer, distributed by G.D. Searle LLC, LAB-0231-4.0, revised January 2008. New York, NY, USA: Pfizer Inc. (available at: http://www. accessdata.fda.gov/drugsatfda_docs/label/2008/012151s062lbl.pdf)
2. Amazit L, Le Billan F, Kolkhof P, Lamribet K, Viengchareun S, Fay MR, Khan JA, Hillisch A, Lombès M, Rafestin-Oblin ME, et al. 2015. Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1. Journal of Biological Chemistry 290:21876-21889. (doi:10.1074/jbc.M115.657957)
3. Arai K, Homma T, Morikawa Y, Ubukata N, Tsuruoka H, Aoki K, Ishikawa H, Mizuno M & Sada T. 2015. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. European Journal of Pharmacology 761:226-234. (doi:10.1016/j.ejphar.2015.06.015)
4. Arai K, Tsuruoka H & Homma T. 2015. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats. European Journal of Pharmacology 769:266-273. (doi:10.1016/j.ejphar.2015.11.028)
5. Arai K, Morikawa Y, Ubukata N, Tsuruoka H & Homma T. 2016. CS-3150, a novel nonsteroidal mineralocorticoid receptor antagonist, shows preventive and therapeutic effects on renal injury in deoxycorticosterone acetate/salt-induced hypertensive rats. Journal of Pharmacology and Experimental Therapeutics 358:548-557. (doi:10.1124/jpet.116.234765)
6. Arhancet GB, Woodard SS, Iyanar K, Case BL, Woerndle R, Dietz JD, Garland DJ, Collins JT, Payne MA, Blinn JR, et al. 2010. Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists. Journal of Medicinal Chemistry 53:5970-5978. (doi:10.1021/jm100506y)
7. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE & Evans RM. 1987. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237:268-275. (doi:10.1126/science.3037703)
8. Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, et al. 2015. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. Mineralocorticoid receptor antagonist tolerability study-diabetic nephropathy (ARTS-DN) study group. JAMA 314:884-894. (doi:10.1001/jama.2015.10081)
9. Bärfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-Pérez S, Heckroth H, Nitsche A, Ergüden JK, Gielen-Haertwig H, Schlemmer KH, et al. 2012. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem 7:1385-1403. (doi:10.1002/cmdc.201200081)
10. Bauersachs J. 2013. The ARTS of third-generation mineralocorticoid receptor antagonists: achieving cardiovascular benefit with minimized renal side effects? European Heart Journal 34 2426-2428. (doi:10.1093/eurheartj/eht235)
11. Bittler D, Hofmeister H, Laurent H, Nickisch K, Nickolson R, Petzoldt K & Wiechert R. 1982. Synthesis of spirorenone-a novel highly active aldosterone antagonist. Angewandte Chemie 94:718. (doi:10.1002/ange.19820940923)
12. Bomback AS, Kshirsagar AV & Klemmer PJ. 2009. Renal aspirin: will all patients with chronic kidney disease one day take spironolactone? Nature Clinical Practice Nephrology 5 74-75. (doi:10.1038/ncpneph1004)
13. Bramlage P, Swift SL, Thoenes M, Minguet J, Ferrero C & Schmieder RE. 2016. Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease. European Journal of Heart Failure 18:28-37. (doi:10.1002/ejhf.444)
14. Brandish PE, Fraley ME, Hershey JC & Steen JT. 2009. Mineralocorticoid Receptor Modulators. Patent WO 2009078934:A1. Kenilworth, NJ, USA: Merck & Co., Inc. (available at: https://www.google.com/patents/WO2009078934A1)
15. Brilla CG, Pick R, Tan LB, Janicki JS & Weber KT. 1990. Remodeling of the rat right and left ventricles in experimental hypertension. Circulation Research 67:1355-1364. (doi:10.1161/01.RES.67.6.1355)
16. Casals-Stenzel J, Buse M, Wambach G & Losert W. 1984. The renal action of spirorenone and other 6β, 7β; 15β, 16β-dimethylene-17-spirolactones, a new type of steroidal aldosterone antagonists. Arzneimittelforschung 34:241-246
17. Cella JA & Kagawa CM. 1957. Steroidal lactones. Journal of the American Chemistry Society 79:4808-4809. (doi:10.1021/ja01574a058)
18. Cella JA & Tweit RC. 1959. Steroidal aldosterone blockers. II. Journal of Organic Chemistry 24:1109-1110. (doi:10.1021/jo01090a019)
19. Chien YW, Hofmann LM, Lambert HJ & Tao LC. 1976. Binding of spirolactones to human plasma proteins. Journal of Pharmaceutical Sciences 65:1337-1340. (doi:10.1002/jps.2600650919)
20. Claire M, Rafestin-Oblin ME, Michaud A, Roth-Meyer C & Corvol P. 1979. Mechanism of action of a new antialdosterone compound, prorenone. Endocrinology 104:1194-1200. (doi:10.1210/endo-104-4-1194)
21. Cook CS, Hauswald CL, Schoenhard GL, Piper CE, Patel A, Radzialowski FM, Hribar JD, Aksamit W, Finnegan P, Bible RH, et al. 1988. Difference in metabolic profile of potassium canrenoate and spironolactone in the rat: mutagenic metabolites unique to potassium canrenoate. Archives of Toxicology 61:201-212. (doi:10.1007/BF00316635)
22. Cook CS, Berry LM, Bible RH, Hribar JD, Hajdu E & Liu NW. 2003. Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans. Drug Metabolism and Disposition 31:1448-1455. (doi:10.1124/dmd.31.11.1448)
23. Corvol P, Michaud A, Menard J, Freifeld M & Mahoudeau J. 1975. Antiandrogenic effect of spirolactones: mechanism of action. Endocrinology 97:52-58
24. Corvol P, Claire M, Oblin ME, Geering K & Rossier B. 1981. Mechanism of the antimineralocorticoid effects of spirolactones. Kidney International 20:1-6. (doi:10.1038/ki.1981.97)
25. Dahlöf CG, Lundborg P, Persson BA & Regårdh CG. 1979. Re-evaluation of the antimineralocorticoid effect of the spironolactone metabolite, canrenone, from plasma concentrations determined by a new high-pressure liquid-chromatographic method. Drug Metabolism and Disposition 7:103-107
26. de Gasparo M, Joss U, Ramjoué HP, Whitebread SE, Haenni H, Schenkel L, Kraehenbuehl C, Biollaz M, Grob J & Schmidlin J. 1987. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. Journal of Pharmacology and Experimental Therapeutics 240:650-656
27. de Gasparo M, Whitebread SE, Preiswerk G, Jeunemaitre X, Corvol P & Menard J. 1989. Antialdosterones: incidence and prevention of sexual side effects. Journal of Steroid Biochemistry 32:223-227. (doi:10.1016/0022-4731(89)90169-6)
28. Dinsdale C, Wani M, Steward J & O'Mahony MS. 2005. Tolerability of spironolactone as adjunctive treatment for heart failure in patients over 75 years of age. Age and Ageing 34:395-398. (doi:10.1093/ageing/afi104)
29. Dorrance AM. 2008. Stroke therapy: is spironolactone the holy grail? Endocrinology 149 3761-3763. (doi:10.1210/en.2008-0724)
30. Drug and Therapeutic Bulletin. 1988. Spironolactone: no longer for hypertension. In Drug and Therapeutic Bulletin, vol. 26, p 88. Eds Andrew Herxheimer. London, UK: Consumers' Association Ltd
31. Ergueden JK, Kolkhof P, Sandner P, Kuhl A, Stasch JP, Pook E & Schlemmer KH. 2005. Fluorenone 1, 4,-Dihydropyridin Derivatives. Patent WO 2005087740:A1. Leverkusen, Germany: Bayer Healthcare AG. (available at: https://google.com/patents/WO2005087740A1)
32. Fagart J, Hillisch A, Huyet J, Bärfacker L, Fay M, Pleiss U, Pook E, Schäfer S, Rafestin-Oblin ME & Kolkhof P. 2010. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. Journal of Biological Chemistry 285:29932-29940. (doi:10.1074/jbc.M110.131342)
33. Feinfeld DA & Carvounis CP. 1978. Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment. JAMA 240:1516. (doi:10.1001/jama.1978.03290140058027)
34. Feldman D, Funder JW & Edelman IS. 1972. Subcellular mechanism in the action of the adrenal steroids. American Journal of Medicine 53:545-560. (doi:10.1016/0002-9343(72)90152-0)
35. Filippatos G, Anker SD, Böhm M, Gheorghiade M, Køber L, Krum H, Maggioni AP, Ponikowski P, Voors AA, Zannad F, et al. 2016. A randomized controlled study of finerenone vs eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. European Heart Journal 37:2105-2114. (doi:10.1093/eurheartj/ehw132)
36. Fitzgerald N & Fitzgerald JD. 2009. Trails of discovery: aldosterone antagonists: a model of translational medicine. Dialogues in Cardiovascular Medicine 14:119-125
37. Funder JW. 2005. Mineralocorticoid receptors: distribution and activation. Heart Failure Reviews 10:15-22. (doi:10.1007/s10741-005-2344-2)
38. Funder JW, Feldman D & Edelman IS. 1972. Specific aldosterone binding in rat kidney and parotid. Journal of Steroid Biochemistry 3:209-218. (doi:10.1016/0022-4731(72)90052-0)
39. Funder JW, Feldman D, Highland E & Edelman IS. 1974. Molecular modifications of anti-aldosterone compounds: effects on affinity of spirolactones for renal aldosterone receptors. Biochemical Pharmacology 23:1493-1501. (doi:10.1016/0006-2952(74)90386-4)
40. Funder JW, Mercer J & Hood J. 1976. SC 23992: radioreceptor assays for therapeutic and side effects. Clinical Science and Molecular Medicine Supplements 51:333s-334s. (doi:10.1042/cs051333s)
41. Funder JW, Pearce PT, Smith R & Campbell J. 1989. Vascular type I aldosterone binding sites are physiological mineralocorticoid receptors. Endocrinology 125:2224-2226
42. Gardiner P, Schrode K, Quinlan D, Martin BK, Boreham DR, Rogers MS, Stubbs K, Smith M & Karim A. 1989. Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. Journal of Clinical Pharmacology 29:342-347
43. Garthwaite SM & McMahon EG. 2004. The evolution of aldosterone antagonists. Molecular and Cellular Endocrinology 217:27-31. (doi:10.1016/j.mce.2003.10.005)
44. Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, Meinke G, Tsai FT, Sigler PB & Lifton RP. 2000. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 289:119-123. (doi:10.1126/science.289.5476.119)
45. Gochman N & Gantt CL. 1962. A fluorimetric method for the determination of a major spironolactone (Aldactone) metabolite in human plasma. Journal of Pharmacology and Experimental Therapeutics 135:312-316
46. Gomez-Sanchez EP. 2016. Third-generation mineralocorticoid receptor antagonists: why do we need a fourth? Journal of Cardiovascular Pharmacology 67 26-38. (doi:10.1097/FJC.0000000000000329)
47. Gomez-Sanchez EP, Fort C & Thwaites D. 1992. Central mineralocorticoid receptor antagonism blocks hypertension in Dahl S/JR rats. American Journal of Physiology 262:E96-E99
48. Grob J, Boillaz M, Schmidlin J, Wehrli H, Wielanol P, Fuhrer H, Rihs G, Joss U, de Gasparo M, Haenni H, et al. 1997. Steroidal aldosterone antagonists: increased selectivity of 9a1 11-epoxy derivatives. Helvetica Chimica Acta 80:566-585. (doi:10.1002/hlca.19970800220)
49. Grune J, Benz V, Brix S, Salatzki J, Blumrich A, Höft B, Klopfleisch R, Foryst-Ludwig A, Kolkhof P & Kintscher U. 2016. Steroidal and nonsteroidal mineralocorticoid receptor antagonists cause differential cardiac gene expression in pressure overload-induced cardiac hypertrophy. Journal of Cardiovascular Pharmacology 67:402-411. (doi:10.1097/FJC.0000000000000366)
50. Haller H, Bertram A, Stahl K & Menne J. 2016. Finerenone: a new mineralocorticoid receptor antagonist without hyperkalemia: an opportunity in patients with CKD? Current Hypertension Reports 18 41. (doi:10.1007/s11906-016-0649-2)
51. Herman E & Rado J. 1966. Fatal hyperkalemic paralysis associated with spironalactone. Observation on a patient with severe renal disease and refractory edema. Archives of Neurology 15:74-77. (doi:10.1001/archneur.1966.00470130078008)
52. Herman TS, Fimognari GM & Edelman IS. 1968. Studies on renal aldosterone-binding proteins. Journal of Biological Chemistry 243:3849-3856
53. Hertz R & Tullner WW. 1958. Progestational activity of certain steroid-17-spirolactones. Proceedings of the Society for Experimental Biology and Medicine 99:451-452. (doi:10.3181/00379727-99-24380)
54. Hofmann LM, Chinn LJ, Pedrera HA, Krupnick MI & Suleymanov OD. 1975. Potassium prorenoate: a new steroidal aldosterone antagonist. Journal of Pharmacology and Experimental Therapeutics 194:450-456
55. Hofmann LM, Weier RM, Suleymanov OD & Pedrera HA. 1977. Mexrenoate potassium: a steroidal aldosterone antagonist and antihypertensive. Journal of Pharmacology and Experimental Therapeutics 201:762-768
56. Hu X, Li S, McMahon EG, Lala DS & Rudolph AE. 2005. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone. Mini-Reviews in Medicinal Chemistry 5:709-718. (doi:10.2174/1389557054553811)
57. Huffman DH, Kampmann JP, Hignite CE & Azarnoff DL. 1978. Gynecomastia induced in normal males by spironolactone. Clinical Pharmacology and Therapeutics 24:465-473. (doi:10.1002/cpt1978244465)
58. Inspra Prescribing Information. 2002. INSPRA (eplerenone) tablets: highlights of prescribing information. Silverspring, MD, USA: FDA, US Food and Drug Administration (available at: http://www. accessdata.fda.gov/drugsatfda_docs/label/2008/021437s006lbl.pdf)
59. Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF, Corvol P & Menard J. 1987. Efficacy and tolerance of spironolactone in essential hypertension. American Journal of Cardiology 60:820-825. (doi:10.1016/0002-9149(87)91030-7)
60. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A & Redelmeier DA. 2004. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. New England Journal of Medicine 351:543-551. (doi:10.1056/NEJMoa040135)
61. Kagawa CM, Cella JA & Van Arman CG. 1957. Action of new steroids in blocking effects of aldosterone and desoxycorticosterone on salt. Science 126:1015-1016. (doi:10.1126/science.126.3281.1015)
62. Kagawa CM, Sturtevant FM & Van Arman CG. 1959. Pharmacology of a new steroid that blocks salt activity of aldosterone and desoxycorticosterone. Journal of Pharmacology and Experimental Therapy 126:123-130
63. Karim A. 1978. Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability. Drug Metabolism Reviews 8:151-188. (doi:10.3109/03602537808993782)
64. Karim A & Brown EA. 1972. Isolation and identification of novel sulfurcontaining metabolites of spironolactone (Aldactone). Steroids 20:41-62. (doi:10.1016/0039-128X(72)90117-1)
65. Kolkhof P & Borden SA. 2012. Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. Molecular and Cellular Endocrinology 350:310-317. (doi:10.1016/j. mce.2011.06.025)
66. Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, Bärfacker L, Eitner F, Albrecht-Küpper B & Schäfer S. 2014. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. Journal of Cardiovascular Pharmacology 64:69-78. (doi:10.1097/FJC.0000000000000091)
67. Kolkhof P, Nowack C & Eitner F. 2015. Nonsteroidal antagonists of the mineralocorticoid receptor. Current Opinions in Nephrology and Hypertension 24:417-424. (doi:10.1097/MNH.0000000000000147)
68. Kolkhof P, Jaisser F, Kim SY, Filippatos G, Nowack C & Pitt B. 2016. Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside. Handbook of Experimental Pharmacology [in press]. (doi:10.1007/164_2016_76)
69. Krause W, Sack C & Seifert W. 1983. Pharmacokinetics of the new aldosterone antagonist, spirorenone, in healthy volunteers after single and repeated daily doses. European Journal of Clinical Pharmacology 25:231-236. (doi:10.1007/BF00543796)
70. Landau RL & Lugibihl K. 1958. Inhibition of the sodium-retaining influence of aldosterone by progesterone. Journal of Clinical Endocrinology and Metabolism 18:1237-1245. (doi:10.1210/jcem-18-11-1237)
71. Landau RL, Bergenstal DM, Lugibihl K & Kascht ME. 1955. The metabolic effects of progesterone in man. Journal of Clinical Endocrinology and Metabolism 15:1194-1215. (doi:10.1210/jcem-15-10-1194)
72. Laurent H, Bittler D, Hofmeister H, Nickisch K, Nickolson R, Petzoldt K & Wiechert R. 1983. Synthesis and activities of anti-aldosterones. Journal of Steroid Biochemistry 19:771-776. (doi:10.1016/0022-4731(83)90010-9)
73. Liddle GW. 1957. Sodium diuresis induced by steroidal antagonists of aldosterone. Science 126:1016-1018. (doi:10.1126/science.126.3281.1016)
74. Liddle GW. 1958. Aldosterone antagonists. Archives of Internal Medicine 102:998-1004. (doi:10.1001/archinte.1958.00260230144018)
75. Liu LC, Schutte E, Gansevoort RT, van der Meer P & Voors AA. 2015. Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease. Expert Opinions on Investigational Drugs 24:1123-1135. (doi:10.1517/135437 84.2015.1059819)
76. Losert W, Casals-Stenzel J & Buse M. 1985. Progestagens with antimineralocorticoid activity. Drug Research 35:459-471
77. Losert W, Bittler D, Buse M, Casals-Stenzel J, Haberey M, Laurent H, Nickisch K, Schillinger E & Wiechert R. 1986. Mespirenone and other 15, 16-methylene-17-spirolactones, a new type of steroidal aldosterone antagonists. Arzneimittelforschung 36:1583-1600
78. Lumb G, Newberne P, Rust JH & Wagner B. 1978. Effects in animals of chronic administration of spironolactone-a review. Journal of Environmental Pathology and Toxicology 1:641-660
79. Mayer DG, Bode G & Radzialowski FM. 1988. Toxikologisches profil von spironolacton und kaliumcanrenoat. In Therapie Mit Aldosteron-Antagonisten. Ed E Mutschler. München-Wien-Baltimore: Urban & Scharzenberg, ISBN 3-541-12741-4
80. McInnes GT, Shelton JR, Harrison IR, Perkins RM & Palmer RF. 1982. Comparison of prorenoate potassium and spironolactone after repeated doses and steady state plasma levels of active metabolites. British Journal of Clinical Pharmacology 13:187-194. (doi:10.1111/j.1365-2125.1982.tb01354.x)
81. McInnes GT, Harrison IR, Shelton JR, Perkins RM & Clarke JM. 1984. Relative potency of prorenoate potassium and spironolactone in attenuating diuretic induced hypokalaemia. British Journal of Clinical Pharmacology 18:169-174. (doi:10.1111/j.1365-2125.1984.tb02449.x)
82. Ménard J. 2004. The 45-year story of the development of an antialdosterone more specific than spironolactone. Molecular and Cellular Endocrinology 217:45-52. (doi:10.1016/j.mce.2003.10.008)
83. Merkus FW, Overdiek JW, Cilissen J & Zuidema J. 1983. Pharmacokinetics of spironolactone after a single dose: evaluation of the true canrenone serum concentrations during 24 hours. Clinical and Experimental Hypertension: Part A, Theory and Practice 5:239-248. (doi:10.3109/10641968309048824)
84. Muhn P, Krattenmacher R, Beier S, Elger W & Schillinger E. 1995. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models. Contraception 51:99-110. (doi:10.1016/0010-7824(94)00015-O)
85. Naegele M, Hernandez AF & Ruschitzka F. 2016. Finerenone in heart failure: walking a fine line. European Heart Journal 37:2115-2117. (doi:10.1093/eurheartj/ehw155)
86. Oppermann JA, Piper C & Gardiner P. 1988. Spironolactone and potassium canrenoate-despite chemical similarities, differing metabolism accounts for different toxicological findings in animals. In Therapie Mit Aldosteron-Antagonisten. Ed E Mutschler. München-Wien-Baltimore: Urban & Scharzenberg, ISBN 3-541-12741-4
87. Overdiek HW & Merkus FW. 1987. The metabolism and biopharmaceutics of spironolactone in man. Reviews on Drug Metabolism and Drug Interactions 5:273-302. (doi:10.1515/DMDI.1987.5.4.273)
88. Parthasarathy HK, Ménard J, White WB, Young WF Jr, Williams GH, Williams B, Ruilope LM, McInnes GT, Connell JM & MacDonald TM. 2011. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. Journal of Hypertension 29:980-990. (doi:10.1097/HJH.0b013e3283455ca5)
89. Pearce P & Funder JW. 1987. High affinity aldosterone binding sites (type I receptors) in rat heart. Clinical and Experimental Pharmacology and Physiology 14:859-866. (doi:10.1111/j.1440-1681.1987.tb02422.x)
90. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J & Wittes J. 1999. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. New England Journal of Medicine 341:709-717. (doi:10.1056/NEJM199909023411001)
91. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J & Gatlin M. 2003. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New England Journal of Medicine 348:1309-1321. (doi:10.1056/NEJMoa030207)
92. Pitt B, Filippatos G, Gheorghiade M, Kober L, Krum H, Ponikowski P, Nowack C, Kolkhof P, Kim SY & Zannad F. 2012. Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. European Journal of Heart Failure 14:668-675. (doi:10.1093/eurjhf/hfs061)
93. Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, Nowack C, Kolkhof P, Kim SY & Zannad F. 2013. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. European Heart Journal 34:2453-2463. (doi:10.1093/eurheartj/eht187)
94. Pongpaew C, Songkhla RN & Kozam RL. 1973. Hyperkalemic cardiac arrhythmia secondary to spironolactone. Chest 63:1023-1025. (doi:10.1378/chest.63.6.1023)
95. Ramsay L, Harrison I, Shelton J & Tidd M. 1975. Relative potency of prorenoate and spironolactone in normal man. Clinical Pharmacology and Therapeutics 18:391-400. (doi:10.1002/cpt1975184391)
96. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, McMahon EG & Delyani JA. 2002. Aldosterone induces a vascular inflammatory phenotype in the rat heart. American Journal of Physiology: Heart and Circulatory Physiology 283:H1802-H1810. (doi:10.1152/ajpheart.01096.2001)
97. Ruilope LM, Nowack C & Bakris GL. 2016. Masked and nocturnal hypertension in the ARTS-DN ABPM sub-study with finerenone. Journal of the American Society of Hypertension 10:(Supplement 1) e7. (doi:10.1016/j.jash.2016.06.021)
98. Sadée W, Dagcioglu M & Schröder R. 1973. Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans. Journal of Pharmacology and Experimental Therapy 185:686-695
99. Seifert W, Groß C, Krais T & Müller U. 1982. Pharmacological investigation on the effect of ZK 35973 (spirorenone INN), a new aldosterone antagonist in man. Acta Endocrinologica 99:(Supplement 246) abstract 106. (doi:10.1530/acta.0.0990III)
100. Selye H. 1942. Production of nephrosclerosis by overdosage with desoxycorticosterone acetate. Canadian Medical Association Journal 47:515-519
101. Selye H. 1946. The general adaptation syndrome and the diseases of adaptation. Journal of Clinical Endocrinology and Metabolism 6:117-230. (doi:10.1210/jcem-6-2-117)
102. Selye H. 1955. Anticortisol action of aldosterone. Science 121:368-369. (doi:10.1126/science.121.3141.368)
103. Selye H. 1960. Protection by a steroid-spirolactone against certain types of cardiac necroses. Proceedings of the Society for Experimental Biology and Medicine 104:212-213. (doi:10.3181/00379727-104-25782)
104. Sica DA. 2005. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Failure Reviews 10:23-29. (doi:10.1007/s10741-005-2345-1)
105. Sturtevant FM. 1992. A lesson to be gained from basic research programs. Current Contents 35:9
106. Smith WG. 1962. Spironolactone and gynaecomastia. Lancet 280:886. (doi:10.1016/S0140-6736(62)90668-2)
107. Svensson M, Gustafsson F, Galatius S, Hildebrandt PR & Atar D. 2004. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? Journal of Cardiac Failure 10 297-303. (doi:10.1016/j.cardfail.2003.10.012)
108. Taylor FF & Faloon WW. 1959. The role of potassium in the natriuretic response to a steroidal lactone (SC-9420). Journal of Clinical Endocrinology and Metabolism 19:1683-1687. (doi:10.1210/jcem-19-12-1683)
109. Thorn GW & Engel LL. 1938. The effect of sex hormones on the renal excretion of electrolytes. Journal of Experimental Medicine 68:299-312. (doi:10.1084/jem.68.3.299)
110. Thosar SS, Gokhale RD & Tolbert DS. 2003. Immediate Release Eplerenone Compositions. Patent US 6558707:B1. Skokie, IL, USA: G.D. Searle & Co. (available at: https://www.google.com/patents/US6558707)
111. Ulmann A, Bertagna C, Le Go A, Husson JM, Tache A, Sassano P, Menard J & Corvol P. 1985. Assessment of the antimineralocorticoid effect of RU 28318 in healthy men with induced exogenous and endogenous hypermineralocorticism. European Journal of Clinical Pharmacology 28:531-535. (doi:10.1007/BF00544063)
112. Vonder Haar TA & Miller M. 1977. Warning: your prescription may be dangerous to your health. In New York Magazine, pp 46-57. New York, NY, USA: New York Media, LLC
113. Weinberger MH, Roniker B, Krause SL & Weiss RJ. 2002. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. American Journal of Hypertension 15:709-716. (doi:10.1016/S0895-7061(02)02957-6)
114. Yang J & Young MJ. 2016. Mineralocorticoid receptor antagonistspharmacodynamics and pharmacokinetic differences. Current Opinions in Pharmacology 27:78-85. (doi:10.1016/j. coph.2016.02.005)
115. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ & Pitt B. 2011. Eplerenone in patients with systolic heart failure and mild symptoms. New England Journal of Medicine 364:11-21. (doi:10.1056/NEJMoa1009492)